predicting immune responses before vaccination is challenging because of the complexity of the governing parameters. nevertheless, recent work has shown that B cell receptor (Bcr)-antigen engagement in vitro can prove a powerful means of informing the design of antibody-based vaccines. We have developed this principle into a two-phased immunogen evaluation pipeline to rank-order vaccine candidates. In phase 1, recombinant antigens are screened for reactivity to the germline precursors that produce the antibody responses of interest. to both mimic the architecture of initial antigen engagement and facilitate rapid immunogen screening, these antibodies are expressed as membrane-anchored IgM (mIgM) in 293F indicator cells. In phase 2, the binding hits are multimerized by nanoparticle or proteoliposome display, and they are evaluated for Bcr triggering in an engineered B cell line displaying the IgM sequences of interest. Key developments that complement existing methodology in this area include the following: (i) introduction of a high-throughput screening step before evaluation of more time-intensive Bcr-triggering analyses; (ii) generalizable multivalent antigen-display platforms needed for Bcr activation; and (iii) engineered use of a human B cell line that does not display endogenous antibody, but only ectopically expressed Bcr sequences of interest. through this pipeline, the capacity to initiate favorable antibody responses is evaluated. the entire protocol can be completed within 2.5 months. B cell reporter system and multivalent antigen display needed for BCR triggering can be established. For antigen multivalency, HIV signaling studies have largely relied on the trivalency of the gp140 structure 7, [9] [10] [11] [12] ; however, we have found that trivalent antigen can be, in some cases, suboptimal for initiating BCR signaling, particularly as germline affinity for antigen is often low 6 . Consequently, this protocol also presents procedures for further arraying antigen through established nanoparticle 26 and proteoliposomal 6, 8 platforms.
IntroDuctIon
The mechanistic basis for differences in vaccine immunogenicity is poorly understood and represents a significant hurdle to elicit effective antibody responses against pathogenic agents. Although it is clear that sustained antibody responses are a function of interactions between dendritic cells, B cells and T cells during germinal center reactions [1] [2] [3] , there is no systematically defined correlate for predicting vaccine efficacy before use 2, 4 . This problem is exacerbated by the fact that certain pathogens display a structure that is both variable and immunogenic, effectively manipulating immunogenicity to ensure that antibody responses are unable to neutralize their targets 4, 5 . We and others have recently developed a new approach to evaluate vaccine candidates [6] [7] [8] [9] [10] [11] [12] . It centers around the premise that antibody responses can be, in part, predicted through a single parameter: reconstituted interactions between the antigen and the germline BCR. Our work has shown that the human antibody V H gene, IGHV1-69, encodes germline BCRs that naturally engage and signal in response to the influenza spike protein hemagglutinin (HA) 6 . Antigen engagement is specific to the HA stem region, which is a functionally conserved epitope for broadly neutralizing antibodies (bnAbs) against the influenza virus [13] [14] [15] [16] [17] . Affinity to the HA stem is provided by a hydrophobic heavy chain complementarity determining region (CDRH2) that is not reconfigured during antibody recombination, predicting that humans are genetically hardwired to generate broad immunity to this virus 6, 18, 19 . Indeed this recognition is then correlated with biased use of IGHV1-69 for influenza bnAb development [13] [14] [15] [16] [17] [18] [19] , suggesting that reconstituted IGHV1-69 BCR-antigen interactions can also be used to inform the design of HA-based subunit vaccines.
Comparison with alternative methods
Since the first demonstration of a relationship between reconstituted BCR signaling and influenza antibody response patterns 6 , the biochemical reconstruction of germline BCR stimulation has been applied to the screening of immunogen candidates for other pathogens-including HIV [7] [8] [9] [10] [11] [12] 20 -and is consequently emerging as an important tool that informs vaccine design 4, 16, 17, [21] [22] [23] . In all cases, the methodology relies on (i) establishing a B cell reporter system in which selected BCR sequences can be ectopically expressed and systematically evaluated for signaling, and (ii) generating multivalent displays of antigens to trigger BCR activation. However, there are some key differences in this protocol that are outlined here.
First, the B cell reporter lines used in other studies, including K46 or WEHI-231 mouse B cells 7, 8 , A20 mouse B cells 11 or the DG-75 human B cell line 7, [9] [10] [11] [12] , are not used in our protocol, as they express endogenous BCR, which can complicate monospecific germline antibody display. For example, DG-75 offers clear advantages over mouse analogs as a human reporter line, but it presents its own IgM BCR, meaning that germline BCRs of interest are expressed and enriched by FACS in an IgG format 7, [9] [10] [11] [12] . Germline activation naturally takes place through IgM BCR, and recent studies have demonstrated marked differences in the kinetics and mechanistic basis of signaling through IgM versus IgG BCR 24, 25 . To generate a human B cell reporter line that facilitates expression of only IgM BCR sequences of interest, this protocol describes generating a clone of the Ramos Burkitt's lymphoma B cell line that presents no endogenous surface antibody 6, 20 .
Triggering in response to a multimerized antigen is measured kinetically by calcium flux and by tyrosine phosphorylation of downstream effectors of BCR signaling, as is the case with all the methodology in this area [6] [7] [8] [9] [10] [11] [12] 20 . However, in contrast to other studies, this protocol uses a rapid pre-selection step wherein candidate immunogens are first evaluated for reactivity to mIgM, which is displayed by 293F cells 6, 18, 19 . This step facilitates expedient rank-ordering of candidate immunogens during which time the
In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates
used for flux experiments include Fluo-3, Fluo-4 and their derivatives, all of which exhibit large fluorescence intensity increases on binding Ca 2+ (ref. 31) . Unlike fura red and Indo-1, there is no accompanying spectral shift. In all cases, baseline emission is recorded, and then calcium flux is measured in real time after the addition of antigen multimer.
To generate multivalent antigen presentations required to initiate signaling, this protocol also provides instructions for generating nanoparticle and proteoliposome configurations of HA, the latter requiring no tailored antigen configuration or structure design effort (Box 1). For nanoparticle design, we use the recently developed HA-ferritin nanoparticle platform 26 as the BCR-stimulating ligand. In this platform, HA monomers are fused with ferritin, which is an iron-sequestering protein that self-assembles into nanoparticles composed of 24 identical polypeptides 26 . Monomeric HA is inserted at the interface of ferritin subunits such that eight trimeric HA spikes are formed during nanoparticle assembly 26 . By contrast, for protoliposome display, pre-purified his-tagged HA trimer is arrayed on the surface of preformed 100-nm liposomes containing Ni-linked phospholipids. Nanoparticles and proteoliposomes can substitute for one another as BCR-stimulating ligands in this protocol. Some HIV-BCR signaling studies have relied on the multivalency provided by recombinant gp140 envelope trimer [8] [9] [10] 12 , whereas we and others have used higher order multimers of monomeric gp120 (refs. 7,20) . For influenza, we have found that HA trimer alone has a very limited capacity to induce germline BCR signaling, This protocol is used to assess whether candidate immunogens can engage and stimulate BCRs of interest; namely, germline antibody sequences that give rise to effective humoral responses after infection with pathogen. The protocol is divided into two phases: phase 1, a rapid screening step wherein antigen interactions with low-affinity germline mIgM are evaluated at the 293F cell surface; and phase 2, a subsequent analysis of the capacity to stimulate BCR activity through the engagement specificity identified in phase 1.
and as a general rule we recommend the use of multimerized antigen formats when the valency and affinity of engagement is low or not yet defined. This is clearly not a requirement for gp140 (refs. 8-10,12) . Nevertheless, increased antigenic valency has long been correlated with heightened immunogenicity for antibody-based vaccines and should therefore be considered during immunogen design 32 .
Phase 1 (Steps 1-47).
In the first phase of this protocol (Fig. 1) , the germline precursor antibody is initially defined through publicly available computer software, and it is then experimentally configured as a mIgM. Next, the germline mIgM is expressed on the surface of 293F cells and is assessed for reactivity to fluorescently labeled antigen. Phase 1 necessitates the use of the following gene constructs:
The variable domains of germline-reverted heavy and light chains from an antibody of interest. Publicly available algorithms that revert antibody sequences to their germline precursors define these sequences. The constant domain for mIgM, obtained from GenBank.
For the germline antibody of interest and for an irrelevant control antibody, either separate plasmids containing the mIgM heavy chain and light chain 6, 20 or a single plasmid containing the mIgM heavy and light chains combined. When cloned together 
Box 1 | Proteoliposome array of His-tagged antigen
This procedure presents the steps to array antigen (produced during Steps 6-30) on liposomal surfaces. It can act as a substitute for nanoparticle or virus-like particle presentations of antigen that often require more structural design effort.
1. Under a gentle stream of nitrogen, evaporate 1 g of DOPC/DGS-NTA(Ni) that has been pre-mixed in a 1:1 molar ratio. This can be done in a 2-ml Eppendorf microtube. 2. For 30 min, rehydrate the dry lipid film in 1,000 µl of HBS while heating it above the melting temperature (T m ) of the lipid mixture. The melting temperature of DOPC is low, but to ensure even distribution with DGS-NTA(Ni), maintain the mixture at at least 50 °C. Intermittent vortexing will also promote lipid-lipid miscibility.  pause poInt A 30-min incubation is sufficient; however, longer periods (2 h) may be used without adverse effects to the experiment. 3. Subject the resulting suspension to ten freeze-thaw cycles using liquid nitrogen and a heating block. 4. Assemble the mini-extruder (100-nm-pore polycarbonate membrane should be sandwiched between two filter supports on either side that have been presoaked in H 2 O). 5. Place the extruder on a heating block and allow it to warm to 50 °C. 6. Equilibrate the extruder in 1 ml of HBS and then remove it from the system. 7. Extrude the lipid mixture 21 times through a 100-nm-pore polycarbonate membrane at 50 °C.  crItIcal step The extrusion step should be performed at 50 °C or above to ensure an even liposome composition. 8. Equilibrate the 100 nm liposomes to RT and mix them with His-tagged antigen at a protein/lipid molar ratio of 1/900 for 1 h.  crItIcal step Although liposome volume is lost in the void during extrusion, the lipid concentration is maintained and thus an accurate protein-to-lipid ratio can be calculated. 9. Adjust the liposome/protein sample to 12.5% (vol/vol) iodixanol (in 1.25 ml HBS) and carefully overlay with 1.75, 0.5 and 0.5 ml of 10, 2.5 and 0% iodixanol in HBS, respectively. This can be done in a 11 × 60 mm ultracentrifuge tube.  crItIcal step Layer the gradient gently to prevent disruption of the gradient. 10. Centrifuge samples for 200,000g in a TH-660 rotor for 2 h at 4 °C. The proteoliposome fraction concentrates at the 2.5-0% iodixanol interface; unbound protein is found in the fractions below. Floating lipid can be visualized by illuminating the gradient with a flashlight (Fig. 8) .  crItIcal step Ensure that the centrifuge tubes are completely filled; otherwise, they will collapse during centrifugation. 11. Collect the proteoliposome fraction and dialyze for at least 3 h using a Slide-A-Lyzer dialysis cassette (10 kDa cutoff )to remove density gradient material. 12. After dialysis, pellet the proteoliposomes (200,000g, 2 h, 4 °C, TH-660 rotor). 13. Resuspend in HBS and measure using a BCA protein assay.  crItIcal step Take care not to dislodge the pellet when aspirating tube.  pause poInt Proteoliposomes should be aliquotted, snap-frozen in liquid nitrogen, and then stored for several months at −80 °C. 14. Apply proteoliposomes in place of nanoparticles to trigger BCR signaling during
Step 78 (Step 78A(iv) for calcium flux;
Step 78B(i) for tyrosine phosphorylation).
tIMInG
Step 1, 30 min; step 2, 30 min; step 3, 20 min; steps 4-7, 30 min; step 8, 1 h; step 9, 20-30 min; step 10, 2 h 30 min; step 11, 3 h; step 12, 2 h; step 13, 1 h; step 14, 2 h (Step 78A, with proteoliposomes) and 1-2 d (Step 78B, with proteoliposomes). ? trouBlesHootInG
step 10
If the lipids are not floating in the gradient, this may be due to the protein being overloaded. This problem can be addressed by decreasing the protein/lipid ratio.
step 13
If the protein yields are low, this could be because the protein has been underloaded. This problem can be addressed by increasing the protein/lipid ratio.
in the same plasmid, sequences should be separated by a furin cleavage site and/or a F2A peptide sequence 8, 9 . A mammalian expression vector encoding recombinant antigen with an AviTag for site-specific biotinylation and fluorescent labeling.
Experimental controls for phase 1. The use of a mature antibody is not obligate, but it can prove to be a useful positive control. If structural information is available, we recommend that antibody-binding mutants be designed as negative controls.
Mutations can be introduced into the recombinant antigen and/or the surface-expressed IgM; both control forms are presented here. To attenuate recognition of the HA stem at the level of the antigen, we introduce I45R/T49R mutations 6 or, alternatively, an N-linked glycosylation site (I45N/G47T) 26 within the stem region.
To attenuate HA stem recognition at the level of the antibody (IGHV1-69 mIgM), we mutate the HA stem contacting CDRH2 (I53A/I54A) 6 . If structural information is not available, specific engagement to the germline mIgM of interest can be defined relative to reactivity to irrelevant mIgM. In all cases, surface IgM expression is co-monitored by fluorescent anti-Ig.
Phase 2 (Steps 48-78).
In the second phase of this protocol ( Fig. 1) , the mIgM constructs are expressed in a reporter B cell line so that the corresponding IgM BCR is produced at the cell surface 6, 20 . Other approaches have used ectopic expression of membrane-anchored IgG or IgM in B cell lines that contain endogenous surface immunoglobulin [7] [8] [9] [10] [11] [12] . For germline stimulation, we favor the use of IgM expressed in Ramos B cells, both because IgM is a natural germline BCR configuration and because in this cell line clones negative for surface IgM can be easily derived, making mono-specific BCR display possible 6, 20 . To stability-integrate mIgM sequences of interest, we use the FEEKW lentiviral expression system that was originally designed to deliver exogenous antibody sequences to hematopoietic B cell progenitors 33 [34] [35] [36] ) that this protocol is unable to address. Rather, we present methodology that rank-orders the capacity to stimulate a specific BCR signature; it should only be applied as an immunogen design principle in that context. Hydrochloric acid (HCl; Sigma-Aldrich, cat. no. H1758) Sodium hydroxide (NaOH; Sigma-Aldrich, S8045) 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC; Avanti Polar Lipids) 1,2-Dioleoyl-sn-glycero-3-(N-(5-amino-1-carboxypentyl)iminodiacetic acid) succinyl (DGS-NTA(Ni)); Avanti Polar Lipids, cat. no. 850375) Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, cat. no. 23227) Chloroform (Alfa Aesar, cat. no. 43685-K2) ! cautIon This is an organic solvent (halogen class) and suspected human carcinogen. Use it in a fume hood. Wear safety goggles, a chemical-resistant lab coat and nitrile gloves (minimum 8 mil). Store it away from direct sunlight and keep it in a dry well-ventilated area. Do not store it with oxidizing compounds, strong bases, or in containers made of aluminum. Methanol (Fisher Scientific, cat. no. BP1105) ! cautIon Methanol is extremely flammable. Use it in a fume hood. Wear safety goggles, a chemical-resistant lab coat and nitrile gloves to prevent exposure. Store it in a dedicated steel flammable cabinet. Liquid nitrogen ! cautIon Extensive tissue damage or burns can result from exposure. Personal protective equipment should include REAGENT SETUP FBS Filter FBS using a 0.22-µm filter, snap-freeze it in liquid nitrogen and distribute it into 25-ml aliquots. FBS can be stored at −80 °C for several months. l-Glutamine, 100× Filter l-Glutamine using a 0.22-µm filter, snap-freeze it in liquid nitrogen and distribute it into 5-ml aliquots. l-Glutamine can be stored at −80 °C for several months. Penicillin/streptomycin, 100× Filter penicillin/streptomycin using a 0.22-µm filter, snap-freeze it in liquid nitrogen and distribute it into 5-ml aliquots. Penicillin/streptomycin can be stored at −80 °C for several months.
Complete RPMI (cRPMI) cRPMI is 15% (vol/vol) FBS + 1× glutamine + 1× penicillin/streptomycin. Remove 85 ml of RPMI from 500 ml of RPMI stock and add 75 ml of FBS + 5 ml of 100× glutamine + 5 ml of 100× penicillin/streptomycin. Filter the solution using a 0.22-µm filter. The solution can be stored at 4 °C for several weeks. cRPMI conditioned medium Grow Ramos cells to a minimum of 1 × 10 6 cells per ml in a T75 flask and culture them for 24 h in a cell culture incubator set to 37 °C and 5% CO 2 saturation. Collect the culture supernatant and filter it using a 0.22-µm filter. The medium can be stored at 4 °C for several weeks. DMEM DMEM is 10% (vol/vol) FBS + 1× glutamine + 1× of penicillin/ streptomycin. Remove 60 ml from 500 ml of DMEM, and then add 50 ml of FBS, 5ml of 100× glutamine + 5 ml of 100× penicillin/streptomycin. Filter the solution using a 0. • 41 or IMGT nomenclature 42 for CDR definitions and numbering. As junctional diversity can make the CDR3 and FR4 sequences difficult to predict 39 , engineer V gene-only reversions of heavy and light chains (FR1, CDR1, FR2, CDR2 and FR3) and retain the mature CDR3 and FR4. Both servers will identify the CDR3 sequences; however, the FR4 sequence is not in the standard output. It consists of the remaining variable region sequence downstream to the CDR3 but preceding the immunoglobulin constant region (the variable and downstream constant regions are demarcated by the amino acid sequence …VSS|X…, Fig. 2 ).
2| Attach a leader sequence to the V gene-reverted variable region. The variable region (V gene-reverted FR1, CDR1, FR2, CDR2, FR3 + mature CDR3 and FR4) is synthesized commercially and should be preceded by leader sequence to direct translation into the lumen of the endoplasmic reticulum (ER). Leader sequences can be analyzed by the SignalP 4.1 server (http://www.cbs.dtu.dk/services/SignalP/) to confirm the presence and location of signal peptide cleavage sites (Fig. 3) .  pause poInt Synthesized DNA may be stored at −20 °C for several months.
3|
Attach the variable domain of the germline-reverted heavy chain to the constant region encoding mIgM. The sequence for mIgM is available in GenBank (accession no. X17115), and it can also be synthesized commercially. As shown in Figure 2 setting. The two important features of the output are: first, the highest scoring V gene alignment (= V gene origin); and second, the position and sequence of the mature CDR3. Information on the D and J genes used to generate the CDR3 is also provided in the output, but it is not displayed or used in this protocol, as this junctional information is often unclear 39 , and it is consequently not standard to germline reversion. domain fragments and the PCR-amplified membrane IgM constant domain 6 . This procedure follows standard PCR methodology and is illustrated using the prototypic influenza HA stem-directed bnAb CR6261 as an example in ). The antigen probe should contain, at either the N or the C terminus, the biotinylatable AviTag sequence GLNDIFEAQKIEWHE, followed by a 6× His-tag for affinity purification. Influenza probes are engineered into VRC8400 as the extracellular domain of HA (A/New Caledonia/20/1999, an H1N1 strain 44 , GenBank accession no. AY289929) fused at the C terminus to the trimeric foldon domain of T4 fibritin followed by the Avi + His-tag 19 . To remove indiscriminant cell surface sialic acid-binding activity by HA, incorporate the mutation Y98F into the receptor-binding site 19 . For HA stem-binding mutants, introduce I45R,T49R substitutions 6 or an N-linked glycosylation site (I45N,G47T) 26 in the stem region. All cloning steps involve standard amplification, digestion and ligation of the antigen probe nucleotide sequence into the desired expression vector. Cloning the HA sequence into the multiple cloning site of VRC8400 can be conveniently achieved using the Xba1 and BamH1 restriction sites. For mutagenesis, use a QuikChange mutagenesis kit.  pause poInt Once the expression vector has been constructed, it can be stored at −20 °C. Depending on the size of the experiment, cells can be transfected in 250-ml, 500-ml, 1-liter or 2-liter baffled flasks with vented lids. To ensure adequate mixing, the culture volume should not exceed one-third of the flask volume when all components are present in the culture. We present conditions to transfect a recombinant antigen into a 500-ml culture volume, with the transfection taking place in a 2-liter baffled flask. For the HA antigen, 500 ml of culture should provide at least 5 mg of protein, which should last for several months during the course of this protocol. Generally protein yield can range from <1 to 15 mg/liter; thus, depending on the construct and expression vector used, culture conditions may have to be scaled up (or down). 6| Grow 293F cells in FreeStyle medium to a culture density of 1.2 × 10 6 cells per ml in a humidity-controlled shaking incubator set to 37 °C, 8% CO 2 saturation, 78% humidity and 120 r.p.m.  crItIcal step Do not let cell density exceed 3 × 10 6 cells per ml, as the cells will move out of the log growth phase, and they will not respond well to transfection. Figure 4 | Overlap PCR to generate the membrane-anchored IgM configuration of germline-reverted antibodies. Two fragments, the variable region (+leader sequence, underlined) and mIgM constant region, are first amplified by individual PCR. Primers for these reactions are displayed in color. We recommend a minimum of 20-bp overlap for the design of primers 3 and 4. After amplification and gel purification of the two fragments, they are combined and subject to another round of PCR using only primers 1 and 4. The resultant combined fragment should run at ~1.8 kb. Primers 1 and 4 should be designed with the appropriate restriction enzyme sites to ligate the combined product into the desired expression vector.
7| In a sterile 50-ml Falcon tube, add 250 µg of filtered DNA from Step 5 to 12.5 ml of prewarmed Opti-MEM.  crItIcal step Filter DNA, Opti-MEM and FreeStyle medium to avoid contamination, as 293F cells cannot be grown with antibiotics. There is no antibiotic in the 293F medium.
8|
In another sterile 50-ml Falcon tube, add 500 µl of 293fectin to 12.5 ml of prewarmed Opti-MEM. Incubate the tube for 5 min at RT.
9|
Combine the two volumes and incubate the mixture for 25 min at RT.
10|
During this incubation, transfer 500 ml of 293F culture (density = 1.2 × 10 6 cells per ml) to a 2-liter baffled flask with a vented lid.
11|
After the 25-min incubation, add the 25 ml of transfection solution from Step 9 to the 2-liter flask and incubate cells in a humidified, shaking incubator set to 37 °C, 8% CO 2 saturation, 78% humidity and 120 r.p.m.
12|
Incubate cells in the cell culture incubator for 5 d.  pause poInt The supernatant may be stored for several days at 4 °C; however, long-term storage is not advisable as protein aggregation may occur.
14|
Using a tangential flow filtration (TFF) setup (30 kDa cutoff), concentrate the supernatant and exchange the buffer with PBS. For a 500-ml supernatant, concentrate the sample down to 100 ml and then add PBS to bring it back to a 500-ml volume. Repeat and concentrate the sample to 100 ml.  crItIcal step Ensure that the TFF system is thoroughly washed between steps with at least 4-6 liters of H 2 O between different samples. Clean the system with 2 liters of 0.1 N NaOH after use. Ensure that the sample lines are clamped to ensure that there is no backflow when the system is not in use.  crItIcal step If immunogens are eventually going be used in non-human primates, then the system must be cleared of endotoxin by means of an overnight soak in 1 N NaOH before use.
15|
Equilibrate Ni-Sepharose with 50 ml of H 2 O. Use 1 ml of resin per 2.5 liters of expression culture. Spin the mixture at 500g for 5 min at 4 °C and re-equilibrate in 50 ml of PBS.
16| Load resin onto a 1.5 × 20-cm glass Econo-Column and wash through with another 50 ml of PBS.
17| Add imidazole to the protein concentrate from
Step 14 to give a final concentration of 20 mM imidazole (from 5 M imidazole stock, add 0.4 ml to the 100 ml concentrate), and load it onto the column prepared in Step 15.
18| Wash the column with six column-volumes of PBS containing 60 mM imidazole. Discard the washes.
19|
Elute the antigen probe from the column with 2-5 column-volumes of PBS containing 500 mM imidazole.
20|
If proceeding to immediate use, concentrate the eluted protein to >1 ml using an Amicon Ultra centrifugal concentrator (30 kDa cutoff) before proceeding to Step 21.  crItIcal step Some FPLC systems have automated sample infusion via a dedicated sample pump. If you are using one of these systems, it is not necessary to concentrate samples to a low injection volume; thus, this step is not needed. ? trouBlesHootInG  pause poInt For overnight storage, dialyze the eluted protein overnight in 4-5 liters of PBS using a Slide-A-Lyzer dialysis cassette. The next day, concentrate the sample as described in this step before proceeding to size-exclusion chromatography (Steps 21-30).
21|
In preparation for size-exclusion FPLC, degas 500 ml of PBS using a Büchner/vacuum flask.  crItIcal step Ensure that degassed PBS is used to avoid bubbles from developing in the column.
22|
Use double-distilled water to wash through the flow path without the column.
23|
Connect a Superdex 200 10/300 column to the flow path FPLC system. Connect during flow to ensure that the column remains under pressure.  crItIcal step Do not exceed the maximal flow rate (0.5 ml/min), as it will damage the column.
24|
Wash through the column with 1.5 column-volumes of PBS.
25|
Wash the 1-ml manual injection loop with 15 ml of H 2 O.
26| Inject 1 ml of sample from
Step 20 into a 1-ml sample loop, or use the automated sample infusion system of the FPLC system if appropriate. ? trouBlesHootInG 27| Run the size-exclusion chromatography program. Key program parameters include emptying the sample loop with 1.1 ml of PBS and automated fraction collection of protein.
28|
Collect fractions (e.g., trimeric HA will elute between 10 and 12 ml).
29|
Pool and concentrate the fractions corresponding to the correct antigen size to 1-2 mg/ml protein. 35| Perform conjugation according to the calculation made in Step 34. In the example provided in Box 2, 10 µl of antigen at 1 µg/µl is added to 103.5 µl of PBS, and then fluorescent PE-streptavidin is added in 2.3-µl increments with a total of five increments. After each stepwise addition of fluorescent label, incubate the mixture for 20 min and set rotating at 4 °C.  pause poInt Fluorescently labeled probes can be stored at 4 °C in opaque microtubes to prevent light damage, but they should be used within 1-2 months.
Box 2 | Example calculation for fluorescent labeling of antigen
The following is a calculation for labeling biotinylated antigen with fluorescent streptavidin through iterative complex formation. The biotinylated antigen is labeled in five increments, such that the molar ratio of probe to streptavidin valency (four protein-binding sites) is 1:1. In this section, we present conditions to express mIgM in 125-ml flasks with 20 ml of culture volume. We find that this is a convenient volume for flow cytometry assays and should not be confused with the larger 293F volumes needed for protein purification in Step 6. 36| Grow 293F cells in FreeStyle medium to a culture density of 1.2 × 10 6 cells per ml in a humidity-controlled shaking incubator set to 37 °C, 8% CO 2 saturation, 78% humidity and 120 r.p.m.  crItIcal step Do not let the cell density exceed 3 × 10 6 cells per ml, as the cells will move out of the log growth phase, and they will not respond well to transfection.
Parameters

37|
In a sterile 2-ml Eppendorf tube, add 10 µg of filtered DNA (generated in Steps 1-4; mIgM heavy chain + light chain) to 500 µl of prewarmed Opti-MEM.  crItIcal step Filter DNA, Opti-MEM and FreeStyle medium to avoid contamination, as 293F cells cannot be grown with antibiotics. There is no antibiotic in the 293F medium.
38|
In another sterile 2-ml Eppendorf tube, add 20 µl of 293fectin to 500 µl of prewarmed Opti-MEM. Incubate the tube for 5 min at RT.
39|
Combine the volumes from Steps 37 and 38 and incubate the mixture for 25 min at RT. During the 25-min incubation, proceed with the next step.
40| During the incubation in
Step 39, transfer 20-ml aliquots of 293F culture (density = 1.2 × 10 6 cells per ml) to separate 125-ml baffled flasks with vented lids (use one flask for each of the following: each mIgM of interest; each IgM control; and each mutant or irrelevant antibody).
41| After the 25-min incubation, add 1 ml of transfection solution from
Step 39 to each flask.
42|
Incubate the cells for 72h in the humidity-controlled shaking incubator set to 37 °C, 8% CO 2 saturation, 78% humidity and 120 r.p.m. Run the samples in duplicate. As described in Step 34, the antigens can be labeled with either PE or APC. To simultaneously confirm surface trafficking of mIgM, PE-conjugated anti-light chain antibodies are also applied to the transfected cells (see Step 45) . Consequently, when using APC-conjugated antigens, two wells are required for each antigen, such that each well will contain the fluorescent antigen and anti-light chain combined together (can test 48 antigens per plate). If the antigen is labeled with PE, then two are needed for the sample, and two additional wells are needed for the light chain-specific antibody (can test 24 per plate). Each fluorescent antigen and fluorescent antibody will be applied in a single fixed concentration, as detailed in Step 45.
44|
After adding the cells to the wells, place them on ice and add 5 µl of ViVid staining solution (total volume = 100 µl of cell suspension in each well). Stain on ice for 15 min. (Fig. 5) . Ideally this step is performed using a flow cytometry cell analyzer capable of automated sampling and analysis from a 96-well format (e.g., the LSR II system with high throughput sampler by BD).
? trouBlesHootInG  pause poInt This marks the end of phase 1. Antigens that are found to engage the mIgM of interest can be analyzed in phase 2.
phase 2, assessing Bcr activation by candidate antigens: generate lentivirus for Bcr delivery • tIMInG 4-5 d
 crItIcal This section describes how to generate a lentivirus encoding the mIgM sequences of interest for stable expression in a B cell line. In this protocol, we use the FEEKW lentiviral expression system that was originally designed to deliver exogenous antibody sequences to hematopoietic B cell progenitors 33 . 48| Clone mIgM heavy chain and light chain sequences generated in Steps 1-3 into a lentiviral expression vector. This involves standard amplification, digestion and ligation of the immunoglobulin gene sequences into the desired expression plasmid. Cloning antibody sequences into the FEEKW plasmid can be achieved easily using Xho1, Xba1, Hpa1 or BamH1 restriction enzyme sites within the multiple cloning sequence this vector. The other components of the FEEKW lentiviral system include a vesicular stomatitis virus glycoprotein (VSVG)-expressing plasmid for envelope pseudotyping 37 and a packaging vector (p∆R8.2 (ref. 38)), which need not be altered.
49|
Grow 293T cells to 80% confluence with DMEM in a 10-cm dish in a cell culture incubator set to 37 °C and 5% CO 2 saturation.  crItIcal step Ensure that 293T cells are neither fully confluent nor <50% confluent. Both conditions will result in lower viral titer.
50|
Three hours before transfection, replace medium with fresh DMEM.
51|
Use the ProFection transfection system to co-transfect 7.5 µg of FEEKW plasmids for the heavy and light chains of interest 33 , 7.5 µg of ∆R8.2 (a packaging vector that under CMV expression produces all necessary HIV-1 trans-acting proteins minus Env 38 ), and 1 µg of VSVG for envelope pseudotyping 37 , as described in the manufacturer's instructions. Incubate the cells in the cell culture incubator overnight.
52|
The next morning after the overnight transfection, replace the medium with fresh DMEM.
53|
Incubate the cells for a further 48-72 h to allow time for cells to produce the virus.
54|
After the 48-72 h viral production period, harvest the virus by spinning the cells at 2,000g for 5 min at 20 °C and collecting 10 ml of supernatant. 55| Filter the supernatant through a 0.45-µm-pore filter.  pause poInt The virus may be divided into 1-ml aliquots, snap-frozen in liquid nitrogen and stored at −80 °C for several months. Alternatively, the virus may be stored for up to two weeks at 4 °C. phase 2, assessing Bcr activation by candidate antigens: isolate and expand ramos B cells that are surface-negative for IgM • tIMInG 3-5 weeks  crItIcal In this section surface-negative Ramos B cells are generated that can then be used to express mIgM sequences of interest, generating mono-specific BCR display. In all cases, culturing takes place in a cell incubator set to 37 °C and 5% CO 2 saturation. 56| Culture wild-type Ramos B cells in cRPMI in the cell culture incubator set to 37 °C and 5% CO 2 saturation. 60| Culture the cells in conditioned medium to 50-80% confluency in 100 µl in a 96-well format, followed by 300 µl, 500 µl, 1 ml and 2 ml in 48-, 24-, 12-and 6-well formats, respectively. This method of scaling up will ensure that the culture density remains high, which is a feature that we find important for growth of this cell type. At the six-well stage, the culture medium may be exchanged for non-conditioned cRPMI and cells may be further scaled up in 5-10 ml in a T25 flask and then in 10-20 ml in a T75 flask. Grow up to 1×10 6 cells per ml in a T75 flask, spin down the cells (1,000g, 5 min at 4 °C), resuspend them in FBS containing 10% (vol/vol) DMSO, transfer them to a cryovial, and freeze them using a cell freezer. Cells will need 3-4 weeks to grow in a T75 flask.
57|
? trouBlesHootInG 61| Perform two additional cycles of sorting and enrichment of light chain/IgM-negative Ramos cells. In these cycles, sort cells in bulk (e.g., 3 × 10 6 cells) and directly culture them in 10-20 ml of cRMPI in a T75 flask. No conditioned medium is needed at this stage.
62| Separate a subset of low-passage-number cells for freezing. Grow the cells in cRPMI to a density of 1 × 10 6 cells per ml in a T75 flask, spin down the cells (1,000g, 5 min at 4 °C), resuspend them in FBS containing 10% (vol/vol) DMSO, transfer them to a cryovial and freeze them using a cell freezer prefilled with 2-propanol according to the manufacturer's instructions. phase 2, assessing Bcr activation by candidate antigens: express mIgM as signaling-competent germline Bcrs • tIMInG 3-4 weeks  crItIcal In this section, lentivirus generated in Steps 48-55 is used to generate B cells expressing BCRs of interest from the IgM-negative Ramos cells generated from Steps 56-62. Individual lentivirus preparations may be titered with surface IgM/anti-light chain co-expression as a readout; the conditions presented give a BCR expression level of <1% after initial infection, indicating a multiplicity of infection (MOI) below 1 (i.e., the BCR-expressing cells have not been infected with multiple copies of virus). In all cases, culturing takes place in a cell incubator set to 37 °C and 5% CO 2 saturation. 63| Spin down (1,000g, 5 min at 20 °C) and resuspend 2 × 10 6 IgM surface-negative Ramos cells grown up in
Step 61 with 2 ml of lentivirus from
Step 55 (1 ml of mIgM heavy chain virus + 1 ml of light chain virus) containing 8 µg/ml Polybrene. The lentivirus can be quantified by p24 ELISA (trouBlesHootInG table) ; however, this is not initially necessary as we find that the conditions presented consistently generate a BCR expression level with MOI <1.
64|
After the overnight lentiviral infection, replace the medium with cRPMI and culture the cells for 3-4 d.  crItIcal step Ensure that the medium is changed back to cRPMI and that the cells are allowed to culture to the point at which they are again dividing. (Fig. 6) . Double-positive cells will be <1% of cells (MOI < 1). Sort as many BCR-expressing cells as possible into 1 ml of conditioned cRPMI.
68| Culture cells to confluency in a 12-well plate in conditioned medium and then scale up to 2 ml in a six-well plate and up to 5-10 ml in a T25 flask. Conditioned medium need not be applied in the T25 flask.
? trouBlesHootInG 69| Perform two or three additional rounds of sorting by FACS to enrich BCR-positive B cells to a minimum of 85% positivity for BCR expression (Fig. 6) . Apply the same gating scheme outlined in Step 67; however, in this step the numbers of positive B cells will be much higher (e.g., 1-3 × 10 6 cells) and can be cultured directly in T25 flasks in cRPMI without conditioning.
70|
Separate a subset of low-passage-number cells for freezing. Grow the cells in cRPMI to a density of 1 × 10 6 cells per ml in a T75 flask, spin down the cells (1,000g, 5 min at 4 °C), resuspend them in FBS containing 10% (vol/vol) DMSO, transfer them to a cryovial and freeze them using a cell freezer prefilled with 2-propanol according to the manufacturer's instructions.  pause poInt Use BCR-enriched Ramos cells in culture for 3 months, during which time BCR positivity should be stable.
71|
To confirm that candidate immunogens engage the BCR format of the antibody sequence of interest, repeat Steps 43-47, except instead of using 293F cells transfected with mIgM, use 2 × 10 6 of mIgM-expressing Ramos B cells generated during Steps 63-70. Similar antigen binding should be seen by the germline antibody sequences of interest displayed in both the 293F system (Fig. 5) and the Ramos B cell system (Fig. 6) . phase 2, assessing Bcr activation by candidate antigens: antigen multimer expression in 293F and purification • tIMInG 6-8 d  crItIcal In this section, soluble trimeric HA is further multimerized to induce BCR signaling. We use the recently developed HA-ferritin nanoparticle platform 26 as the BCR-stimulating ligand in this section. As for the earlier part of the PROCEDURE, in which the monomeric antigen probe is expressed and purified (Steps 6-30), production of HA-ferritin involves expression in 293F and purification through affinity chromatography and size-exclusion FPLC. In addition, there is an ion-exchange FPLC step that is used to purify control empty ferritin nanoparticles. Different FPLC manufacturers will have different instrument settings; however, the steps listed should be universal.  crItIcal A high-throughput method of arraying the His-tagged antigen probes from phase 1 (Steps 6-30) on the surface of 100-nm liposomes is also described (Box 1) and can be used as an alternative to Steps 72-77. As nanoparticle systems must be tailored to each individual antigen, a high-throughput method can be helpful. Proteoliposome preparations such as those used in Box 1 can be used in place of nanoparticle scaffolds for BCR-triggering analyses 6, 20 . 72| Clone HA-ferritin nanoparticle 26 into a mammalian expression vector (e.g., VRC8400). As with construction of antibody plasmids (Steps 1-4), nucleotide sequences can be synthesized commercially and then incorporated into the desired (ii) After 15 min of exposure at RT, place the cells at 4°C, wash twice with PBS and lyse for 10 min in lysis buffer supplemented with protease inhibitors.  crItIcal step Ensure that the protein lysate is kept on ice to minimize proteolysis in the sample. (iii) Pellet the cellular debris at 2,000g for 5 min, and then collect and measure the protein content of the supernatant using a BCA protein assay.
? trouBlesHootInG  pause poInt Samples may be stored at −20 °C before western blotting. (iv) Run 50 µg of supernatant on SDS-PAGE and western blot for phosphotyrosine, molecular weight 75 kDa (p75) using 4G10 pY (refs. 6,45,46); anti-human actin can also be used as a loading control (Fig. 7) . Quantify total phosphotyrosine intensity by densitometry (Image Processing in Java (ImageJ) Software (http://imagej.nih.gov/ij/) + curve area density calculation in Microsoft Excel). p75 intensity can be standardized to the actin signal. To compare multiple BCRs, the level of phosphorylation after anti-IgM cross-linking must be equivalent.  crItIcal step Densitometry should reflect the calculation of the total area under the curve, and not the peak intensity value.
? trouBlesHootInG Troubleshooting advice can be found in table 1. The column has collapsed The flow rate was too high Invert the column and run it at a lower flow rate (continued)
• tIMInG Steps 1-4, phase 1, antigen screening through 293F cell surface expression and binding: engineer germline mIgM: ~3 weeks; germline mIgM design takes 1 d, and germline variable region synthesis takes 3 weeks; transgene cloning can be completed in 3 d
Step 5 
antIcIpateD results
In our experience, all antigens that engage low-affinity germline IgM, expressed either as membrane-anchored antibody at the surface of 293F cells or in Ramos BCR format, will trigger BCR signaling upon antigen multimerization. For example, using 293F-displayed germline CR6261 IgM, a precursor for developing HA stem-directed bnAbs within the IGHV1-69 lineage 6 , we observe reactivity to fluorescently labeled HA trimer during phase 1 (Fig. 5) . Moreover, stem recognition does not occur in the absence of the IGHV1-69 CDRH2 loop (despite equivalent trafficking to the cell surface) or when the I45R/T49R mutation is inserted into the step epitope (Fig. 5) . Similarly, we do not observe binding to irrelevant mIgM (VRC01, an anti-HIV immunoglobulin; Fig. 5 ). In phase 2, this mIgM is then stably expressed as an IGHV1-69 BCR in a clone of Ramos B cells lacking surface Ig (Fig. 6) . The CR6261 germline mIgM, now in BCR format, shows identical HA stem-binding characteristics as was seen in the 293F system (Fig. 6) . With this 'correct' antigenicity in place, we can also observe BCR signaling in response to HA displayed on a multimeric ferritin nanoparticle (Fig. 7) . Signaling is measured both by calcium flux and tyrosine phosphorylation of downstream BCR effectors (e.g., p75 (refs. 6,45,46) ). Critically, triggering does not occur in the absence of the stem-contacting IGHV1-69 CDRH2 loop (despite equivalent signaling in response cross-linking by anti-IgM) or in response to empty ferritin nanoparticles (Fig. 7) . From these data, we can conclude that HA-ferritin nanoparticle can engage and induce signaling through the stem-specific germline IGHV1-69 BCR.
Although arrayed antigen will ultimately be preferred for vaccine immunogenicity 27, 47 , the 'equivalency' between mIgM binding and BCR triggering allows for faster comparison of different antigens, different BCR sequences, and is not reliant on the time-consuming design of multimeric antigen display. Moreover, once a germline-engaging antigen has been identified, its capacity to induce signaling can then be immediately confirmed in the context of proteoliposome array (Fig. 8) , during which time other multivalent immunogen display platforms may also be explored. Presented are the silver-stained fractions of that gradient, along with an unloaded control antigen. Membrane bound material is recovered at the 2.5/0% (vol/vol) iodixanol interface. Proteoliposomes can then be quantified by BCA protein assay and used to assess BCR triggering in phase 2.
